

PRESS RELEASE

Danish Biopharmaceutical Leader AFYX Therapeutics A/S Secures DKK 25 million in Funding to Drive Product Development and Global Expansion

Copenhagen, Denmark – December 19, 2025

AFYX Therapeutics A/S, a pioneering Danish biopharmaceutical company specializing in reversed innovation and the repurposing of established pharmaceutical substances, has successfully raised DKK 25 million in its latest funding round. This milestone will support the company's efforts to advance its product pipeline, scale operations, and expand its footprint across the European Union and other global markets.

The funding round was led by existing investors and employees and highlights the robust internal and external trust in AFYX's mission and strategic direction. The new funds will accelerate the development of the company's leading products, including its **clobetasol patch for oral lichen planus** and **esketamine therapy for cluster headaches**. Additionally, the capital will fuel AFYX's commercial expansion into new markets, organizational growth, and broader international partnerships.

Claus Møller-San Pedro
CEO & Founder

“We are thrilled to have secured this significant investment, which will enable us to advance our mission of developing transformative biopharmaceutical solutions,” said Dr. Claus Møller San Pedro, CEO and co-founder of AFYX Therapeutics. “The continued trust from our investors reflects their confidence in our team and vision. With their ongoing support, we're well-positioned to address critical unmet medical needs and deliver groundbreaking therapies that improve patient outcomes.”

Since its formation in January 2024, through the merger of three highly experienced pharmaceutical innovators, AFYX Therapeutics has made remarkable progress. Over its first year, the company has accelerated its research and development activities, expanded its commercial reach, and secured new international distribution partnerships, paving the way for sustained growth and innovation.

For more information: <https://afytx.com>

For more information please contact: Helle Heidensleben; hh@afytx.com; +453162 7798

